Strain Data Sheet

RBRC02343

Strain Information

Image
BRC No.RBRC02343
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameB6.129P2-Nf2<tm2Gth>
Former Common nameNf2flox2 (B6)
H-2 Haplotype
ES Cell line
Background strain
Appearance
Strain developmentDeveloped by Drs. Marco Giovannini and Gilles Thomas, INSERM in 1988.
Strain descriptionNf2, neurofibromatosis 2 is a tumor suppressor gene encoding a putative cytoskeletal associated protein. This conditional knockout mouse has a loxP-flanked Nf2 allele. Conditional Nf2 deficient mice can be generated by crossing with tissue-specific Cre mice.
Colony maintenance
References
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.
Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff J M, Berns A, Thomas G
Genes Dev., 14, 1617-1630 (2000). 10887156

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Nf2neurofibromin 211Nf2targeted mutation 2, Gilles Thomas
  • familial meningioma(MedGEN)

  • meningioma(DisGeNET)

  • neurofibromatosis type 2(DisGeNET, MedGEN)
    • more 1 Diseases
  • schwannomatosis 1(MedGEN)
    • loxPphage P1 loxP11loxP
  • familial meningioma(MedGEN)

  • meningioma(DisGeNET)

  • neurofibromatosis type 2(DisGeNET, MedGEN)
    • more 1 Diseases
  • schwannomatosis 1(MedGEN)
    • loxPphage P1 loxP11loxP
  • familial meningioma(MedGEN)

  • meningioma(DisGeNET)

  • neurofibromatosis type 2(DisGeNET, MedGEN)
    • more 1 Diseases
  • schwannomatosis 1(MedGEN)

    • Phenotype

    Annotation by Mammalian phenotyhpe ontology
  • normal phenotype(MP:0002873)
    • Detailed phenotype data

    Ordering Information

    Donor DNAPhage P1 loxP sites, mouse Nf2 genomic DNA
    Research applicationCre/loxP system
    Specific Term and ConditionsIn publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Genes Dev., 14, 1617-1630 (2000). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.
    RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.
    In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
    DepositorMarco Giovannini (INSERM)
    Strain Statusan icon for Frozen spermFrozen sperm
    Strain AvailabilityRecovered litters from cryopreserved sperm (2 to 4 months)
    Cryopreserved sperm (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Order form (Japanese / English)
    2. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    3. Acceptance of responsibility for living modified organism (Japanese / English)

    Genotyping protocol -PCR-

    BRC mice in Publications

    No Data